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BACKGROUND: Expression of ABCG2 is normally absent or low in the pancreas, but high in human pancreatic cancer cells.
The mechanism by which ABCG2 is altered in human cancers remains unknown.
METHODS: We investigated ABCG2 expression in four pancreatic cancer cell lines, and used three microRNA (miRNA) target
prediction programmes, and information from the existing literature to predict and identify hsa-miR-520h as an miRNA that targets
ABCG2. The function of this miRNA was investigated by transient transfection of the pancreatic cancer cell line PANC-1 with
oligonucleotides that mimic hsa-miR-520h.
RESULTS: Results showed that both mRNA and protein levels of ABCG2 were reduced, indicating that it was a target of hsa-miR-520h.
Introduction of hsa-miR-520h mimics into PANC-1 cells also resulted in inhibition of cell migration and invasion, and reduction of side
population cells. Cell proliferation, cell cycle progression and apoptosis were not affected.
CONCLUSIONS: We propose that the effects of hsa-miR-520h may be, at least in part, caused by its regulation of ABCG2. Thus, our
findings provide a new insight into the function of miRNA in the regulation of ABCG2 expression in pancreatic cancer. Gene therapy
using miRNA mimics may therefore be useful as a pancreatic cancer therapy.
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Pancreatic cancer is the fourth leading cause of cancer-related
death in Western countries and has the lowest patient survival rate
of any solid cancer (Jemal et al, 2009). One of the main reasons for
its mortality is that pancreatic cancer cells have a high potential for
invasion and metastasis. Although invasion and migration are the
overwhelming causes of mortality in patients with solid tumours,
our understanding of their molecular determinants is limited
(Fidler, 2003; Weigelt et al, 2005; Gupta and Massague ´, 2006).
Studies on tumour invasion and metastasis have revealed a critical
role for microRNAs (miRNAs), which are small, endogenous non-
coding RNAs that post-transcriptionally regulate a variety of genes
pivotal for invasion or metastasis (Lim et al, 2005; Dalmay and
Edwards, 2006; Kim et al, 2008).
Expression of ABCG2, also known as breast cancer resistance
protein, is normally absent or low in the pancreas (Doyle et al,
1998; Fetsch et al, 2006). However, recent studies show that ABCG2
is overexpressed in pancreatic cancer cells (Ko ¨nig et al, 2005;
Olempska et al, 2007; Guo et al, 2009), in which it alters the cellular
epigenetic programming to promote cell survival. Moreover,
ABCG2 expression is high in side-population cells of pancreatic
and other tumour cell lines, as well as in primary tumour samples
(Hirschmann-Jax et al, 2004; Seigel et al, 2005; Haraguchi et al,
2006; Shi et al, 2008; Sung et al, 2008; Dou et al, 2009; Wang et al,
2009; Yajima et al, 2009), in which it is likely to have a key role in
xenobiotic protection, and acts as a marker of side-population
cells. However, the mechanism by which ABCG2 becomes over-
expressed in human cancers remains unknown, and relatively little
is known about the mechanisms that normally regulate ABCG2
expression. Previous studies suggested that it may be regulated by
DNA methylation (To et al, 2006; Turner et al, 2006),
50-untranslated region (UTR) variation (Nakanishi et al, 2006),
or histone modification (To et al, 2008a). Cytokines and growth
factors (Evseenko et al, 2007; Yin et al, 2008), such as transforming
growth factor-b, tumour necrosis factor- a, interleukin 1- b, and
insulin-like growth factor 2, are proposed to be involved in ABCG2
regulation. The surface protein levels of ABCG2 do not correlate
well with mRNA levels in pancreatic cancer cells (Guo et al, 2009),
suggesting that protein-regulatory mechanisms, such as post-
transcriptional regulation, post-translational modifications, pro-
teolysis, or sequestration in cell compartments, may affect the
protein, without changing the transcript levels. Therefore,
additional investigations of ABCG2 expression mechanisms in
pancreatic cancer are needed.
miRNAs regulate gene expression post-transcriptionally, by
pairing with complementary nucleotide sequences in the 30-UTR of
specific target mRNAs (Pillai, 2005; Zamore and Haley, 2005). They
also have an important role in regulating diverse cellular processes,
including proliferation, differentiation, cell cycle regulation, and
apoptosis (Liao et al, 2008; Wang et al, 2008, 2009, 2009;
Bandi et al, 2009; Bhattacharya et al, 2009; Noonan et al, 2009;
Ribas et al, 2009; Saito et al, 2009; Song et al, 2009; Ostenfeld et al,
2010; Spizzo et al, 2010). miRNAs can function either as tumour
suppressors or as oncogenes, depending on the genes they
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starget (Si et al, 2007; Welch et al, 2007; Aguda et al, 2008;
Grady et al, 2008; Agirre et al, 2009; Furuta et al, 2009; Gandellini
et al, 2009; Hoffman et al, 2009; Hurst et al, 2009; Lee et al, 2009;
Sachdeva et al, 2009; Tsang and Kwok, 2009; Wu et al, 2009;
Aqeilan et al, 2010). Deletion or loss of a suppressive miRNA
results in overexpression of target oncogenes, or conversely,
activation or overexpression of an oncogenic miRNA results in
silencing of tumour-suppressor targets. Thus, oncogenic miRNAs
are usually overexpressed in tumours. For example, miR-125a,
miR-10a, miR-21, miR-222, miR-125b, miR-7, miR-452, miR-10b,
miR-373, and miR-520c induce cell migration and invasion when
overexpressed in tumours or tumour cell lines (Ma et al, 2007;
Asangani et al, 2008; Huang et al, 2008; Yan et al, 2008; Zhang
et al, 2008; Zhu et al, 2008; Cowden Dahl et al, 2009; Qian et al,
2009; Veerla et al, 2009; Weiss et al, 2009). In contrast, suppressive
miRNAs such as miR-193b, miR-122, miR-15a, miR-16–1,
miR-200, miR-221, miR-126*, miR-335, miR-146a, and miR-29c
lead to carcinogenesis, tumour growth, and invasion when
downregulated (le Sage et al, 2007; Bonci et al, 2008; Korpal
et al, 2008; Lin et al, 2008; Musiyenko et al, 2008; Sengupta et al,
2008; Tavazoie et al, 2008; Coulouarn et al, 2009; Li et al, 2009).
In this study, on the basis of previous reports (Liao et al, 2008;
To et al, 2008b), we investigated whether hsa-miR-520h targets
ABCG2 mRNA. We also investigated the role of hsa-miR-520h in
proliferation, cell cycle progression, apoptosis, migration, and
invasion in PANC-1 cells. As side-population cells of pancreatic
cancer that overexpress ABCG2 have been identified as promoting
carcinogenesis (Ho et al, 2007; Shi et al, 2008; Dou et al, 2009;
Wang et al, 2009), we also investigated the effects of hsa-miR-520h
on these cells. We determined whether the effects of hsa-miR-520h
are linked to downregulation of ABCG2 expression. On the basis of
our findings, we propose a model explaining how loss of hsa-miR-
520h expression and subsequent activation of ABCG2 expression
are critical events in the invasion and migration of human
pancreatic cancer cells.
MATERIALS AND METHODS
Cell culture
Human pancreatic cancer cell lines BxPC-3, CFPAC-1, PANC-1,
and SW1990 were obtained from Shanghai Cell Bank (Shanghai,
China), and propagated in our laboratory by culturing in
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carls-
bad, CA, USA) supplemented with 10% fetal bovine serum (FBS,
Sigma, St Louis, MO, USA), 2mM glutamine, 100 mgml
 1
penicillin, and 100mgml
 1 streptomycin. All cells were incubated
at 371C in a humidified chamber supplemented with 5% CO2.
Target prediction
Three online programs, miRanda (http://www.microrna.org/
microrna/home.do), TargetScan (http://www.targetscan.org), and
TarBase (http://diana.cslab.ece.ntua.gr/tarbase), were used in
combination with previous reports, for predicting miRNAs that
might target ABCG2. PANC-1 cells overexpressing ABCG2 were
used for target miRNA verification.
miRNA transfection
miRNAs were designed and synthesised by Genepharma (Shanghai,
China). hsa-miR-520h mimics were sense: 50-ACAAAGUGCUUCC
CUUUAGAGU-30 and anti-sense: 50-UCUAAAGGGAAGCACUUU
GUUU-30. Negative controls were sense: 50-UUCUCCGAACGUGU
CACGUTT-30 and anti-sense: 50-ACGUGACACGUUCGGAGAATT-30.
MicroRNA transfection was performed using Lipofectamine 2000
(Invitrogen). PANC-1 cells were grown in six-well plates to 50%
confluence before transfection. Total RNA and protein were extracted
a t2 4 hp o s t - t r a n s f e c t i o na n du s e df o rq u a n t i t a t i v er e a l - t i m eP C R
(qRT–PCR) and western blot analysis. Transfections were the
following: hsa-miR-520h mimics (miR-520h), negative control miRNA
mimics (NC) and blank control culture medium (Mock).
qRT–PCR and western blot
Total RNA was extracted from cultured or transfected cells using
Trizol (Invitrogen). ABCG2 mRNA was detected by qRT–PCR
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Figure 1 Expression of ABCG2 in four pancreatic cancer cell lines.
(A) Western blot. b-Actin was used as an internal loading control.
(B) Quantitative real-time PCR for relative expression of ABCG2 with
normalisation to b-actin.
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Figure 2 hsa-miR-520h targets ABCG2. (A) The ABCG2 protein in
PANC-1 cells by western blot at 24h post-transfection of hsa-miR-520h
mimic. b-Actin was used as an internal loading control. hsa-miR-520h
mimics (miR-520h), negative control miRNA mimics (NC), and blank
control culture medium (mock). (B) ABCG2 mRNA levels were analysed
by qRT–PCR at 24h post-transfection of hsa-miR-520h mimic and
normalised to b-actin. *Po0.05.
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s(Takara, Dalian, China) and normalised to b-actin. Polymerase
chain reaction primers used were the following: ABCG2 sense: 50-
AATACATCAGCGGATACTACAGAG-30, anti-sense: 50-AGCCACC
ATCATAAGGGT AAACAT-30; b-actin sense: 50-AGAAAATCTGGC
ACCACACC-30, anti-sense: 50-TAGCACAGC CTGGATAGCAA-30.
Reactions were performed using an ABI PRISM 7000 Sequence
Detection system (Applied Biosystems, Foster City, CA, USA).
Cultured or transfected cells were lysed using RIPA buffer with 1%
PMSF. Protein concentration was estimated using a BCA kit
(Keygen, Nanjing, China). Protein was resolved with 10% SDS–
PAGE and transferred to polyvinylidene difluoride (PVDF)
membranes, which were blocked with 5% non-fat milk in Tris-
buffered saline for 3h and incubated overnight with primary
antibodies against ABCG2 (Abcam, Cambridge, MA, USA) or
b-actin (Santa Cruz, Santa Cruz, CA, USA). Membranes were
incubated for 2h with horseradish peroxidase-conjugated goat
anti-rabbit or goat anti-mouse (Santa Cruz) secondary antibody
and visualised with an electrochemiluminescence kit (Pierce,
Rockford, IL, USA).
Cell proliferation, cell cycle, and apoptosis analysis
Cell proliferation was determined using an MTT assay. PANC-1
cells were seeded in 96-well culture plates (Costar, Cambridge) at a
density of 1 10
3 cells per well, transfected with the indicated
miRNA and incubated for 24h before adding 10ml of MTT reagent
to each well and incubating at 371C for 4h; thereafter, the medium
was replaced with 150ml dimethyl sulphoxide (DMSO) and
oscillated for 10min. Viable cells were measured by absorbance
at 490nm wavelength using a microplate reader.
Cell cycle and apoptosis were assessed by flow cytometry
(Becton Dickinson, San Jose, CA, USA). PANC-1 cells were grown
and transfected as above. For cell cycle analysis, cells were
collected, washed with phosphate-buffered saline (PBS) and fixed
in ethanol at  201C overnight before being collected by
centrifugation, washed with PBS, and resuspended in 500mlo f
PBS with 0.2% Triton X-100, 10mM EDTA, 100mgml
 1 RNase A,
and 50mgml
 1 propidium iodide (PI) at room temperature for
30min. For cell apoptosis, cells were collected, washed with PBS,
suspended in 100ml1  binding buffer, stained with 5ml annexin-
fluorescein isothiocyanate (FITC), and 5ml PI at room temperature
for 15min in the dark.
Cell migration and invasion analysis
Cell migration and invasion were assayed using a chamber of
6.5mm in diameter, with 8mm pore size (Corning, Corning, NY,
USA). At 24h post-transfection, PANC-1 cells were added to the
upper chamber, which was coated with 1mgml
 1 matrigel for
invasion assays, and 0.6ml of 10% FBS-DMEM was added to the
lower chamber. Cells were incubated for 24h at 371C, and non-
migrating or non-invading cells were removed with cotton swabs.
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Figure 3 Effect of hsa-miR-520h on cell proliferation, cell cycle, and apoptosis of PANC-1 cells. (A) The proliferation ability of PANC-1 cells at 24h
post-transfection with hsa-miR-520h mimic was detected by MTT assay. The data are mean ± s.d. from three independent experiments (*P40.05, compared
with controls). (B) Cell cycle analysis of PANC-1 cells at 24h post-transfection was analysed by flow cytometry. 2N: cells have diploid DNA content; 4N: cells have
tetraploid DNA content. (C) Apoptosis of PANC-1 cells at 24h post-transfection was monitored by flow cytometry. LR is indicative of apoptosis.
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sCells migrating to or invading the bottom of the membrane were
stained with 0.1% crystal violet for 30min at 371C, and washed
with PBS. Stained cells were soaked in 33% ice-cold acetic acid and
oscillated for 10min. Cell migration or invasion was assessed by
absorbance at 570nm wavelength using a microplate reader
(Tecan, Shanghai, China).
Side-population cell analysis
For analysis of side-population cells, PANC-1 cells were transfected
with miRNA for 24h, then incubated with Hoechst 33342
(5mmolml
 1, Sigma) for 90min at 371C, either alone or in
combination with 50mmol per ml verapamil. Cells were analysed in
a FACS Vantage cell sorter (Becton Dickinson) using dual-
wavelength analysis (blue 425nm, red 675nm) after excitation
with 350nm UV light. Propidium iodide-positive cells were
excluded.
Statistical analysis
Each experiment was conducted at least three times. All values
were reported as mean ± s.d. Differences between experi-
mental groups and controls were assessed by Student’s t-test
using Excel software. Po0.05 was considered statistically
significant.
RESULTS
Pancreatic cancer cell lines expressed variable levels of
ABCG2
Recent studies have revealed that ABCG2 is overexpressed in many
human cancers. Therefore, we checked the expression of ABCG2 in
four human malignant pancreatic cancer cell lines: BxPC-3,
CFPAC-1, PANC-1, and SW1990. BxPC-3 and CFPAC-1 are low-
grade cancer cell lines, and PANC-1 and SW1990 are high-grade
lines. Western blot analysis showed that ABCG2 was overexpressed
in PANC-1 and SW1990 cells, and underexpressed in BxPC-3
and CFPAC-1 cells (Figure 1A). These results were confirmed by
qRT–PCR analysis (Figure 1B).
hsa-miR-520h targets ABCG2
Using miRNA target predicting programmes and previous reports,
we hypothesised that the miRNA hsa-miR-520h targeted ABCG2,
and we chose PANC-1 cells to test our hypothesis. To verify our
predicted target of hsa-miR-520h, we transfected PANC-1 cells
with hsa-miR-520h mimics (miR-520h), negative control miRNA
mimics (NC), and blank control culture medium (mock). Western
blot analysis showed that, at 24h post-transfection, overexpression
of hsa-miR-520h resulted in a significant decrease of endogenous
ABCG2 protein levels, compared with cells transformed with NC or
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Figure 4 Overexpression of hsa-miR-520h inhibits cell migration and invasion of PANC-1 cells. PANC-1 cells were transfected with hsa-miR-520h,
NC, or mock-transfected, then subjected to transwell assays, as described in Materials and Methods. After 24h, cells were stained and measured.
(A) Representative photographs of migrating or invading cells. (B, C) Average OD value of migration or invasion from three independent experiments
± s.d. (B) Cell migration. (C) Cell invasion. *Po0.05.
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smock (Figure 2A). Inhibition of expression by miRNAs mediates
mRNA levels; hence we used qRT–PCR to examine ABCG2’s
mRNA levels. Overexpression of hsa-miR-520h in PANC-1 cells led
to a corresponding decrease of endogenous ABCG2 mRNA at 24h
post-transfection (Figure 2B). These observations suggested that
hsa-miR-520h downregulates ABCG2 expression by inhibiting
translation or causing mRNA instability. Taken together, these
data indicate that hsa-miR-520h targets ABCG2.
Effects of hsa-miR-520h on proliferation, cell cycle, and
apoptosis
To investigate whether hsa-miR-520h influenced cell proliferation,
cell cycle, or apoptosis of PANC-1 cells by inhibiting translation of
the indicated target ABCG2 mRNA, we transiently transfected
PANC-1 cells with hsa-miR-520h mimics for 24h. Ectopic
expression of hsa-miR-520h had no significant inhibition on cell
proliferation compared with that of control groups (Figure 3A).
The cell cycle distribution of transfected cells was examined by
flow cytometry, with no significant G0/G1 accumulation phenotype
in PANC-1 cells transfected with hsa-miR-520h (56.43%) com-
pared with NC (55.34%) or mock (49.68%) control-transfected
cells (Figure 3B). We also examined the cell apoptosis of
transfected cells by flow cytometry, and found no significant
increase in apoptosis in PANC-1 cells transfected with hsa-miR-
520h (7.31%) compared with NC (6.45%) or mock (5.70%)
transfected cells (Figure 3C).
hsa-miR-520h inhibits migration and invasion of PANC-1 cells
To determine whether hsa-miR-520h and its target gene are
associated with tumour migration and invasion, we transfected
PANC-1 cells with hsa-miR-520h mimics or NC, or subjected them
to mock transfection, and evaluated cell migration and invasion.
As shown in Figure 4A and B, the migration ability of hsa-miR-
520h mimic-transfected cells was significantly decreased by 55%,
compared with that of controls. A matrigel invasion assay was
performed in parallel to determine the effect of transfection with
hsa-miR-520h mimics. As shown in Figure 4A and C, the invasion
ability of hsa-miR-520h-transfected cells was significantly
decreased by 53%, compared with that of controls. Taken together,
these results suggested that hsa-miR-520h functions as a potent
suppressor of PANC-1 cell migration and invasion through
downregulation of ABCG2 expression.
hsa-miR-520h depletes the side population of PANC-1 cells
Previous studies suggested that ABCG2 has an important role in
the identity of side-population cells. Therefore, we examined the
influence of hsa-miR-520h on the population of tumour cells
that exclude Hoechst 33342 dye, a strategy that is used to identify
side-population cells. Flow cytometry of hsa-miR-520h-trans-
fected PANC-1 cells showed that the side population was
1.51%, compared with 2.79% in NC-transfected and 3.06% in
mock-transfected cells (Figure 5). These data indicated that
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Figure 5 Overexpression of hsa-miR-520h decreases the side-population compartment of PANC-1 cells. Side-population cells of PANC-1 cells
transfected with hsa-miR-520h account for 1.51% of the total number of cells, compared with 2.79% for NC-treated, or 3.06% for mock-treated, as
measured by FACS analysis.
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population, through downregulation of ABCG2 expression.
DISCUSSION
To investigate the interaction between miRNAs and their target
genes in pancreatic cancer, we determined the expression levels of
ABCG2 in four pancreatic cancer cell lines. Both western blot and
qRT–PCR analysis showed that the cell lines expressed variable
levels of ABCG2, with high expression in PANC-1 and SW1990
cells, and low expression in BxPC-3 and CFPAC-1 cells (Figure 1).
We used miRNA target prediction programmes and previous
studies to find an miRNA that potentially regulated ABCG2, and
selected PANC-1 cells for verification using transfected miRNA
mimics. In the transfected cells, ABCG2 was downregulated at both
the mRNA and protein levels by the proposed target miRNA,
hsa-miR-520h (Figure 2). These data suggested that ABCG2 is a
target of hsa-miR-520h in pancreatic cells.
Overexpression of ABCG2 promotes migration and invasion in a
variety of different tumour types (Mohan et al, 2006; Ho et al,
2007; Chiou et al, 2008; Okamoto et al, 2009). The mechanism by
which ABCG2 becomes overexpressed is not entirely clear, but a
possible mechanism is through miRNA regulation. MicroRNAs can
function as tumour suppressors, oncogenes, or as promoters or
suppressors of metastasis. We transfected hsa-miR-520h into
PANC-1 cells and observed cell proliferation, cycle, apoptosis,
migration, and invasion. Introduction of hsa-miR-520h resulted in
a significant decrease in cell migration and invasion, but with no
significant effects on cell proliferation, cell cycle distribution, or
apoptosis (Figures 3 and 4). This is the first study to show that
hsa-miR-520h inhibits migration and invasion in pancreatic cancer
cells, through a possible mechanism of negative regulation of
ABCG2 expression.
In this study, FACS analysis at 24h after transfection of PANC-1
cells with miRNA mimics showed a remarkable decrease in the
proportion of side-population cells (Figure 5). Therefore, we
propose that hsa-miR-520h may have a critical role in carcino-
genesis by way of affecting side-population cells by influencing
ABCG2 expression. However, Patrawala et al (2005) reported
that ABCG2-positive and -negative tumour cells have similar
tumourigenicity; hence, the precise reasons why ABCG2 is
associated with pancreatic cancer cells require further study.
In conclusion, we show that hsa-miR-520h has a key role not
only in inhibiting migration and invasion, but also in decreasing
the proportion of side-population cells of PANC-1. The possible
mechanism of these effects may be through downregulation of
ABCG2 expression. As no effective approaches for curing
pancreatic cancer exist at present, we propose that gene therapy
targeting hsa-miR-520h/ABCG2 should be investigated further as a
potential alternative therapeutic strategy for pancreatic cancer.
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